Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.593
AS - Asia 13.555
EU - Europa 7.630
SA - Sud America 2.108
AF - Africa 322
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
Totale 40.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.286
SG - Singapore 4.648
VN - Vietnam 2.664
CN - Cina 2.258
IT - Italia 2.092
HK - Hong Kong 1.980
BR - Brasile 1.604
RU - Federazione Russa 1.485
CA - Canada 1.091
IE - Irlanda 932
DE - Germania 788
SE - Svezia 577
FR - Francia 404
GB - Regno Unito 393
IN - India 342
BD - Bangladesh 327
ID - Indonesia 242
UA - Ucraina 216
AR - Argentina 196
FI - Finlandia 180
KR - Corea 176
TR - Turchia 142
ZA - Sudafrica 129
MX - Messico 121
NL - Olanda 114
IQ - Iraq 109
JP - Giappone 107
PK - Pakistan 105
AT - Austria 78
EC - Ecuador 73
PL - Polonia 73
ES - Italia 71
SA - Arabia Saudita 69
CO - Colombia 65
UZ - Uzbekistan 65
PH - Filippine 55
CH - Svizzera 45
MA - Marocco 44
PY - Paraguay 36
CL - Cile 35
VE - Venezuela 34
BE - Belgio 30
PE - Perù 29
DK - Danimarca 28
EG - Egitto 28
MY - Malesia 28
KE - Kenya 26
AE - Emirati Arabi Uniti 24
JO - Giordania 24
TN - Tunisia 24
TW - Taiwan 23
AU - Australia 22
JM - Giamaica 22
UY - Uruguay 19
CZ - Repubblica Ceca 18
DZ - Algeria 17
PT - Portogallo 17
TH - Thailandia 17
NP - Nepal 15
HN - Honduras 14
AZ - Azerbaigian 13
BO - Bolivia 13
DO - Repubblica Dominicana 13
IL - Israele 13
LT - Lituania 13
RO - Romania 12
ET - Etiopia 11
KZ - Kazakistan 10
OM - Oman 10
PS - Palestinian Territory 10
SN - Senegal 10
AL - Albania 9
CR - Costa Rica 9
KG - Kirghizistan 9
IR - Iran 8
LB - Libano 8
BY - Bielorussia 7
MN - Mongolia 7
NG - Nigeria 7
RS - Serbia 7
BB - Barbados 6
BG - Bulgaria 6
BH - Bahrain 6
GE - Georgia 6
GR - Grecia 6
HU - Ungheria 6
NI - Nicaragua 6
GT - Guatemala 5
LV - Lettonia 5
NZ - Nuova Zelanda 5
PA - Panama 5
QA - Qatar 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
CI - Costa d'Avorio 4
HR - Croazia 4
KH - Cambogia 4
LY - Libia 4
MT - Malta 4
MU - Mauritius 4
Totale 40.176
Salva come PNG Salva come JPEG
Città #
Singapore 2.673
Hong Kong 1.950
Ann Arbor 1.515
Ashburn 1.380
Fairfield 1.223
San Jose 1.079
Dublin 912
Toronto 904
Ho Chi Minh City 827
Hanoi 653
Wilmington 605
Woodbridge 518
Seattle 514
Frankfurt am Main 509
New York 505
Chandler 474
Houston 472
Milan 438
Dallas 426
Cambridge 390
Santa Clara 383
Chicago 376
Princeton 370
The Dalles 320
Beijing 309
Los Angeles 302
Hefei 275
Dearborn 272
Lauterbourg 214
Jakarta 182
Moscow 169
Seoul 164
Altamura 160
Nanjing 158
São Paulo 157
Council Bluffs 155
Jacksonville 154
Lawrence 139
Buffalo 137
Boardman 126
Rome 126
Helsinki 119
Haiphong 103
Shanghai 103
Da Nang 94
Munich 87
Ottawa 81
San Diego 80
London 79
Orem 78
Johannesburg 66
Andover 65
Tokyo 65
Guangzhou 63
Nuremberg 63
Tashkent 59
Rio de Janeiro 57
Warsaw 55
Montreal 50
Shenyang 47
Dong Ket 46
Hải Dương 46
Vienna 44
Biên Hòa 43
Mexico City 42
Hebei 41
Ha Long 40
Can Tho 39
Chennai 39
Denver 39
Stockholm 39
Atlanta 38
Lappeenranta 37
Baghdad 36
Brasília 36
Monza 36
Salt Lake City 36
Fremont 35
Nanchang 35
Phoenix 35
Amsterdam 34
Dhaka 34
Zurich 34
Naples 33
Ninh Bình 33
Quận Bình Thạnh 32
Thái Nguyên 32
Bologna 31
Jinan 30
Brooklyn 29
Bắc Ninh 29
Changsha 29
Poplar 29
Mumbai 28
Columbus 27
Lahore 27
Porto Alegre 27
Ankara 26
Elk Grove Village 26
Jiaxing 26
Totale 25.407
Salva come PNG Salva come JPEG
Nome #
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 522
Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases 509
Diagnostic delay in bronchiectasis: an Italian perspective 440
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 435
Early referral to palliative care services in patients with IPF: A tool to take a step forward 395
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 369
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 360
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases 357
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 356
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 352
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 349
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 348
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 336
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 332
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 303
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 303
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 300
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 296
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 292
Janus-faced amiodarone-induced pneumopathy 291
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 287
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 285
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 283
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 274
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 274
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 274
A multidisciplinary approach to screen the post-COVID-19 conditions 266
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 266
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 258
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 255
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 247
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 247
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 244
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 243
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis 243
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 243
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 242
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review 240
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 239
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 238
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 235
Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD 232
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 231
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 229
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 225
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 219
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 219
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 217
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 216
Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis 215
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 214
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 212
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach 210
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 208
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 208
Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection 207
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 207
Diagnosis of asthma and copd 205
Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population 203
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 203
Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case 200
Alteration of Lipid Metabolism in Patients with IPF and Its Association with Disease Severity and Prognosis: A Case–Control Study 199
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 199
Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach 195
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 193
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 193
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 193
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 192
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 192
Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution 190
Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers 186
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 185
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease 184
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 184
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 182
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 181
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 179
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 178
Clinical Impact of Vaping 178
The Multiple Components of COPD 177
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 176
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 175
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia 175
Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences 174
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 174
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases 173
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 173
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 172
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 171
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 171
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 168
Management of Idiopathic Pulmonary Fibrosis 168
Guiding ILD management in systemic autoimmune rheumatic diseases 167
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 166
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 165
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 165
Update in chronic obstructive pulmonary disease 2006 164
How do Climate Conditions and Urbanization Impact Non-Tuberculous Mycobacteria Infections? An Italian nationwide case-control study 163
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 163
Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation 163
Totale 23.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.830
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.830
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021205 0 0 0 0 0 0 0 0 0 0 0 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20257.621 400 1.168 430 326 609 308 546 218 687 1.115 586 1.228
2025/202619.442 2.499 1.593 1.480 2.077 1.812 1.010 2.647 1.029 1.685 1.508 1.618 484
Totale 41.306